skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Zosyn® (piperacillin/tazobactam) reformulation: Expanded compatibility and coadministration with lactated Ringer’s solutions and selected aminoglycosides

Review

(2507) Views  (917) Full article downloads

Authors: Narendra R Desai, Syed M Shah, Jonathan Cohen, Matthew McLaughlin, Hema R Dalal

Published Date April 2008 Volume 2008:4(2) Pages 303 - 314
DOI: http://dx.doi.org/10.2147/TCRM.S2564

Narendra R Desai, Syed M Shah, Jonathan Cohen, Matthew McLaughlin, Hema R Dalal

Formulation Development, Wyeth Research, Pearl River, NY, USA

Abstract: Zosyn®, also known as Tazocin® for injection, contains piperacillin and tazobactam and was approved by the US Food and Drug Administration in 1993 for the treatment of indicated serious infections. In 1995, United States Pharmacopoeia and European Pharmacopoeias reduced the particulate limit for injectables by 40%, based on general safety concerns. Wyeth attempted to control sporadic batch failures (associated with increased particulate formation) by shortening product expiration dating from 36 to 24 months and optimizing the stopper siliconization process. These modifications did not correct the problem completely. Wyeth reformulated Zosyn by incorporating two stabilizing functional excipients, ethylene diamine tetraacetic acid disodium salt (EDTA disodium) and sodium citrate, which solved the particulate formation problem. These two functional excipients also allowed for the first time Y-site coadministration of reformulated Zosyn product with amikacin and gentamicin at specific doses and concentrations, and with certain diluents, and the use of Ca++ ion-containing Lactated Ringer’s for admixture preparation. Reformulated Zosyn (approved 2005) may provide useful options of drug administration to healthcare professionals to lessen levels of particulates. Supportive data is provided for the expanded compatibility of reformulated Zosyn with different types of Ringer’s solutions used globally and for the Y-site coadministration of amikacin and gentamicin aminoglycosides.

Keywords: Zosyn®, aminoglycoside, piperacillin, particulate matter








Readers of this article also read:

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)
Cost-effectiveness analysis of electrochemotherapy with the Cliniporator™ vs other methods for the control and treatment of cutaneous and subcutaneous tumors
Developments in the management of autosomal dominant polycystic kidney disease
Docetaxel for the post-surgery treatment of patients with node-positive breast cancer
Review of the combined contraceptive vaginal ring, NuvaRing®
Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome
New approaches to managing asthma: a US perspective
A review of nasal polyposis
Fluticasone furoate nasal spray in the treatment of allergic rhinitis
Nonlinear analysis of the heartbeats in public patient ECGs using an automated PD2i algorithm for risk stratification of arrhythmic death